Establishment of a model for predicting the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis

Longchuan ZHU; Wei WU; Bo ZOU; Dakai GAN; Xue LIN; Wei ZHOU; Molong XIONG

doi:10.3969/j.issn.1001-5256.2022.11.012

Volume 38 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(11): 2499-2504

PDF( 2187 KB)

Establishment of a model for predicting the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis

DOI: 10.3969/j.issn.1001-5256.2022.11.012

Longchuan ZHU^{1a
,
,
,},
Wei WU²,
Bo ZOU^1a,
Dakai GAN^1a,
Xue LIN^1a,
Wei ZHOU^1b,
Molong XIONG^1a

1a.
Department of Liver Disease, The Ninth Hospital of Nanchang, Nanchang 330002, China
1b.
Department of Information Technology, The Ninth Hospital of Nanchang, Nanchang 330002, China
2.
Department of Digestion, Children's Hospital of Jiangxi Province, Nanchang 330000, China

Research funding:

Key Research and Development Program of Jiangxi Province (20181BBG78010)

More Information

Corresponding author: ZHU Longchuan, zlcy1984@sina.com(ORCID: 0000-0002-4461-6195)
Received Date: 2022-04-05
Accepted Date: 2022-05-07
Published Date: 2022-11-20

Abstract

Abstract

Objective To investigate the factors for predicting the efficacy of third-generation cephalosporin (3^rd GC) in the treatment of community-acquired spontaneous bacterial peritonitis (CASBP), and to establish and validate an efficacy predictive model for 3^rd GC in the treatment of CASBP. Methods A retrospective analysis was performed for the clinical data of the patients with liver cirrhosis and CASBP who received 3^rd GC monotherapy for initial treatment in The Ninth Hospital of Nanchang, and according to their treatment outcome, they were divided into non-response group and response group. The patients hospitalized from 2013 to 2018 were included in the modeling cohort (55 patients the non-response group and 110 in the response group), and those hospitalized from 2019 to 2020 were included in the validation cohort (17 patients in the non-response group and 43 in the response group). In the modeling cohort, the two groups were compared in terms of the indices including general information, underlying diseases, past history, clinical manifestation, and laboratory test results. Univariate analyses (the t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups; the chi-square test or the Fisher's exact test was used for comparison of categorical data between groups) and a binary Logistic regression analysis were used to identify efficacy predictors, and an efficacy predictive model was established based on the logistic regression equation. The receiver operating characteristic (ROC) curve was plotted to perform internal and external validations of the model in the modeling cohort and the validation cohort, respectively. Results The study population had a mean age of 51.6±12.0 years, and male patients accounted for 80.0%; hepatitis B was the main cause of liver cirrhosis (66.7%), and 3^rd GC had an overall response rate of 68.0%. In the modeling cohort, compared with the response group, the non-response group had significantly lower proportion of patients with the first onset of SBP, polymorphonuclear (PMN) count in ascites, and leukocyte count in ascites (all P < 0.05), as well as significantly higher proportion of patients with exposure to broad-spectrum antibiotic and platelet count (both P < 0.05). The Logistic regression analysis showed that the first onset of SBP (odds ratio [OR]=0.158, 95% confidence interval [CI]: 0.064-0.392, P < 0.001), ascites PMN count (OR=0.728, 95%CI: 0.530-0.998, P=0.046), exposure to broad-spectrum antibiotic (OR=9.152, 95%CI: 1.513-55.351, P=0.016), and platelet count (OR=1.012, 95%CI: 1.006-1.019, P < 0.001) were independent predictive factors for non-response to 3^rd GC. The efficacy predictive model had an area under the ROC curve (AUC) of 0.840, and based on the maximum Youden index, predictive score ≥ 0.207 was the optimal cut-off value for predicting non-response, with a corresponding Youden index of 0.536, a sensitivity of 89.1%, a specificity of 63.6%, a positive predictive value of 55.1%, and a negative predictive value of 92.1%. This model had an AUC of 0.837 in the validation cohort. Conclusion The first onset of SBP and higher ascites PMN count are the protective factors against non-response to 3^rd GC for the treatment of CASBP, and exposure to broad-spectrum antibiotic and higher platelet count are the risk factors for such non-response. The model established for predicting the efficacy of 3^rd GC in the treatment of CASBP has good predictive performance and thus holds promise for clinical application.
- Liver Cirrhosis,
- Peritonitis,
- Community-Acquired Infections,
- Cephalosporins,
- Logistic Models

FullText(HTML)

References(15)

References

[1]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the management of ascites and complications in cirrhosis[J]. J Chin Hepatol, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003. 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南[J]. 临床肝胆病杂志, 2017, 33(10): 1847-1863. DOI: 10.3969/j.issn.1001-5256.2017.10.003.
[2]	BIGGINS SW, ANGELI P, GARCIA-TSAO G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 74(2): 1014-1048. DOI: 10.1002/hep.31884.
[3]	FIORE M, GENTILE I, MARAOLO AE, et al. Are third-generation cephalosporins still the empirical antibiotic treatment of community-acquired spontaneous bacterial peritonitis? A systematic review and meta-analysis[J]. Eur J Gastroenterol Hepatol, 2018, 30(3): 329-336. DOI: 10.1097/MEG.0000000000001057.
[4]	PUGH RN, MURRAY-LYON IM, DAWSON JL, et al. Transection of the oesophagus for bleeding oesophageal varices[J]. Br J Surg, 1973, 60(8): 646-649. DOI: 10.1002/bjs.1800600817.
[5]	KAMATH PS, WIESNER RH, MALINCHOC M, et al. A model to predict survival in patients with end-stage liver disease[J]. Hepatology, 2001, 33(2): 464-470. DOI: 10.1053/jhep.2001.22172.
[6]	SUNJAYA DB, LENNON RJ, SHAH VH, et al. Prevalence and predictors of third- generation cephalosporin resistance in the empirical treatment of spontaneous bacterial peritonitis[J]. Mayo Clin Proc, 2019, 94(8): 1499-1508. DOI: 10.1016/j.mayocp.2018.12.036..
[7]	PEDUZZI P, CONCATO J, KEMPER E, et al. A simulation study of the number of events per variable in Logistic regression analysis[J]. J Clin Epidemiol, 1996, 49(12): 1373-1379. DOI: 10.1016/s0895-4356(96)00236-3.
[8]	TAY P, XIAO J, TAN D, et al. An epidemiological meta-analysis on the worldwide prevalence, resistance, and outcomes of spontaneous bacterial peritonitis in cirrhosis[J]. Front Med (Lausanne), 2021, 8: 693652. DOI: 10.3389/fmed.2021.693652.
[9]	SARWAR S, TARIQUE S, WARIS U, et al. Cephalosporin resistance in community acquired spontaneous bacterial peritonitis[J]. Pak J Med Sci, 2019, 35(1): 4-9. DOI: 10.12669/pjms.35.1.17.
[10]	Ministry of Health of the People's Republic of China. Regulations for clinical application of antibacterial agents[J]. Chin J Clin Infect Dis, 2012, 5(4): 193-196. DOI:10.3760/cma.j.issn. 1674-2397.2012.04.001. 中华人民共和国卫生部. 抗菌药物临床应用管理办法[J]. 中华临床感染病杂志, 2012, 5(4): 193-196. DOI: 10.3760/cma.j.issn.1674-2397.2012.04.001.
[11]	ZHU LC, GAN DK, HU QQ, et al. Predictive factors for third-generation cephalosporin- resistant spontaneous bacterial peritonitis[J]. J Chin Hepatol, 2019, 35(7): 1501-1504. DOI: 10.3969/j.issn.1001-5256.2019.07.016. 朱龙川, 甘达凯, 胡青青, 等. 第三代头孢菌素耐药的自发性细菌性腹膜炎发生的预测因素[J]. 临床肝胆病杂志, 2019, 35(7): 1501-1504. DOI: 10.3969/j.issn.1001-5256.2019.07.016.
[12]	ARIZA X, LORA-TAMAYO J, CASTELLOTE J, et al. Polymorphonuclear counts in ascitic fluid and microorganisms producing spontaneous bacterial peritonitis: an under-recognized relationship[J]. Scand J Gastroenterol, 2013, 48(10): 1213-1221. DOI: 10.3109/00365521.2013.832367.
[13]	ZHANG GY, TIAN CY, HU H. Recent progress in immune dysfunction of neutrophils in patients with cirrhosis[J]. Chin Gen Pract, 2021, 24(21): 2734-2743. DOI: 10.12114/j.issn. 1007-9572.2021.00.457. 张国远, 田彩云, 胡晗. 肝硬化患者中性粒细胞免疫功能障碍的研究进展[J]. 中国全科医学, 2021, 24(21): 2734-2743. DOI: 10.12114/j.issn.1007-9572.2021.00.457.
[14]	MISHRA D, DAS AK, CHAPAGAIN RH, et al. Thrombocytosis as a predictor of serious bacterial infection in febrile infants[J]. J Nepal Health Res Counc, 2019, 16(41): 401-404. DOI: 10.33314/jnhrc.v16i41.1673.
[15]	YUAN SN, ZHAO JJ, HAN XY, et al. Influence of bacterial and fungal infections on platelets[J]. Chin J Nosocomiol, 2016, 26(22): 5083-5086. DOI: 10.11816/cn.ni.2016-154312. 袁胜男, 赵俊暕, 韩晓燕, 等. 细菌与真菌感染对血小板的影响研究[J]. 中华医院感染学杂志, 2016, 26(22): 5083-5086. DOI: 10.11816/cn.ni.2016-154312.

Relative Articles

[1]	Jinqiu YANG, Wenxia ZHAO, Cheng ZHOU, Tong LIU. Risk factors for the development of advanced liver fibrosis in nonalcoholic fatty liver disease and establishment of a nomogram model[J]. Journal of Clinical Hepatology, 2024, 40(8): 1579-1584. doi: 10.12449/JCH240812
[2]	Jing KUANG, Shuangqin TENG, Tongtong SHEN, Yiran YAN, Wei WANG, Chuan SHEN, Caiyan ZHAO. Risk factors for portopulmonary hypertension in liver cirrhosis and construction of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1802-1806. doi: 10.12449/JCH240914
[3]	Decai KONG, Xiaojing ZHANG, Yangguang YUN, Haoyu DUAN, Junfeng YE. Risk factors for biliary stricture and prognosis after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2024, 40(11): 2253-2259. doi: 10.12449/JCH241119
[4]	Mingqiang ZHU, Dashuai YANG, Junpeng PEI, Xiangyun XIONG, Yang SU, Youming DING. Analysis of influencing factors on biliary complications after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2023, 39(7): 1627-1632. doi: 10.3969/j.issn.1001-5256.2023.07.017
[5]	Sufang LU, Rui HUANG, Hongli ZHAO, Dandan WANG, Yuzhen DING, Hong ZHOU. Value of a risk assessment model in predicting venous thromboembolism in patients with liver failure after artificial liver support therapy[J]. Journal of Clinical Hepatology, 2023, 39(3): 613-619. doi: 10.3969/j.issn.1001-5256.2023.03.019
[6]	Bingbing ZHU, Jinxiang YANG, Qun ZHANG, Fangyuan GAO, Xianbo WANG. Risk factors for the 90-day prognosis of patients with type I hepatorenal syndrome and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2022, 38(7): 1561-1565. doi: 10.3969/j.issn.1001-5256.2022.07.019
[7]	Perioperative Management Group, Chinese Society of Organ Transplantation, Chinese Medical Association. Expert consensus on perioperative vascular complications for liver transplantation(2021)[J]. Journal of Clinical Hepatology, 2021, 37(9): 2054-2057. doi: 10.3969/j.issn.1001-5256.2021.09.010
[8]	Bing GUO, Mingquan PANG, Xiaolei XU, Junwei HAN, Haijiu WANG. Establishment and evaluation of a nomogram for predicting post-hepatectomy complications in two types of hepatic echinococcosis[J]. Journal of Clinical Hepatology, 2021, 37(11): 2626-2631. doi: 10.3969/j.issn.1001-5256.2021.11.027
[9]	Yun ZHAO, Lijin ZHAO. Research advances in the risk factors for infection after liver transplantation[J]. Journal of Clinical Hepatology, 2021, 37(8): 1957-1962. doi: 10.3969/j.issn.1001-5256.2021.08.046
[10]	Mingwei LI, Jian GAO, Xiangwei ZHAI, Xiangjun QIAN, Xiajie WEN, Mingjie YAO, Zhaojun DUAN, Erjiang ZHAO, Ling ZHANG, Fengmin LU. Construction and analysis of a predictive model for posthepatectomy recurrence in patients with hepatocellular carcinoma based on preoperative CXCL13 measurement[J]. Journal of Clinical Hepatology, 2021, 37(4): 823-828. doi: 10.3969/j.issn.1001-5256.2021.04.020
[11]	Wang Han, Zuo XiangRong, Cao Quan. Predictive factors and interventions for prolonged mechanical ventilation after liver transplantation[J]. Journal of Clinical Hepatology, 2020, 36(7): 1658-1662. doi: 10.3969/j.issn.1001-5256.2020.07.047
[12]	Zhang DaLi, Feng DanNi, Zhang LiJuan, Tang RuJia, He Xi, Zhou Xia, Gao YinJie, Liu ZhenWen, Liu HongLing. Risk factors for recurrence after liver transplantation in patients with hepatocellular carcinoma and their prognosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1985-1989. doi: 10.3969/j.issn.1001-5256.2020.09.015
[13]	Zheng WeiPing, Shen ZhongYang. Risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma and related control strategies[J]. Journal of Clinical Hepatology, 2019, 35(11): 2391-2395. doi: 10.3969/j.issn.1001-5256.2019.11.003
[14]	Chen Long, Li Yue. The risk factors and prediction systems for posthepatectomy complications[J]. Journal of Clinical Hepatology, 2019, 35(1): 217-221. doi: 10.3969/j.issn.1001-5256.2019.01.048
[15]	Jie EnBo, Xuan FengHui, Sun XiaoDong, Sun DaWei, Lu: GuoYue. An analysis of risk factors for early complications after liver transplantation[J]. Journal of Clinical Hepatology, 2018, 34(6): 1282-1288. doi: 10.3969/j.issn.1001-5256.2018.06.030
[16]	Zhang YinTao, Meng JinYing, Guo ChunGuang, Wang Hua. Risk factors for biliary complications after common bile duct exploration combined with primary suture[J]. Journal of Clinical Hepatology, 2017, 33(2): 304-307. doi: 10.3969/j.issn.1001-5256.2017.02.021
[17]	Wang XinWei, Zhao ZongGang. Risk factors for infectious complications after hepatectomy in patients with intrahepatic bile duct stones[J]. Journal of Clinical Hepatology, 2017, 33(9): 1754-1757. doi: 10.3969/j.issn.1001-5256.2017.09.025
[18]	Wang MingYue, Lu ZhiYan. Imaging evaluation of complications after liver transplantation[J]. Journal of Clinical Hepatology, 2016, 32(12): 2295-2299. doi: 10.3969/j.issn.1001-5256.2016.12.013
[19]	Lu: GuoYue. Risk factors for biliary complications after liver transplantation from donation after cardiac death[J]. Journal of Clinical Hepatology, 2015, 31(12): 2027-2030. doi: 10.3969/j.issn.1001-5256.2015.12.009
[20]	Chen Man, Zhang Xia. Research advances in molecular prediction of recurrence and metastasis of primary liver cancer after liver transplantation[J]. Journal of Clinical Hepatology, 2014, 30(12): 1361-1365. doi: 10.3969/j.issn.1001-5256.2014.12.032

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	李正优，李荷，周俊. 预见性护理结合舒适护理干预在肝移植术后患者中的应用. 西藏医药. 2024(06): 123-125 .
2.	李珊珊，王媛，高春辉. 早期下床活动对肝移植术后患者胃肠功能及下肢血流的影响. 国际移植与血液净化杂志. 2023(01): 41-44 .
3.	张欣悦，王海刚，王昊，杨传伟. 他克莫司治疗1例肝移植术后患者的药学监护. 中国医药导报. 2023(14): 183-187 .
4.	种庚，彭晓春，吴若林，赵红川，邵敏. 成人肝移植术后早期严重并发症相关危险因素分析. 肝胆外科杂志. 2022(06): 454-459 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(2) / Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (407) PDF downloads(43)

Establishment of a model for predicting the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis

DOI: 10.3969/j.issn.1001-5256.2022.11.012